Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects - FIND-MORE

Erasmus Medical Center0 个研究点目标入组 32 人开始时间: 2020年10月8日最近更新: 2021年1月18日

适应症

试验速览

暂无简介。

•- Able to tolerate the [18F]DPA-714 PET-MRI scan procedures and to make an informed decision to participate in this study
•- Symptomatic patients must meet clinical criteria for FTD clinical syndromes
•- Presymptomatic individuals and healthy controls must show no objective evidence of cognitive impairment
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 27
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•- Has contraindications for MRI scanning, e.g. metal objects in the body, claustrophobia
•- Has evidence of structural brain abnormalities that are likely to interfere with the interpretation of PET scan
•- Has one or more comorbidities that may interfere with the outcomes of the study (e.g. significant immune disease, neurological disease, CNS malignancy)
•- Has a history of moderate or severe traumatic brain injury
•- Has made use of immunomodulatory or immunosuppressive therapy in the 3 months prior to the scan
•- Has any disease or uses medication that may compromise the function of the body systems and could interfere with the metabolism of the radiotracer or the interpretation of the results
•- Has an unstable medical condition
•- Is pregnant or breastfeeding
•- Has a history of severe drug allergy or hypersensitivity
•- Has been injected with a previously administered radiopharmaceutical within 6 terminal half-lives OR when the total yearly radiation exposure exceeds 10 mSv if participating in this protocol
•- Is a low-affinity binder for the tracer based on the rs6971 TSPO polymorphism
•- Has a present or past history of alcohol and/or drug abuse
•- Makes use of benzodiazepines and is not able to suspend their use during the week prior to the PET scan

发起方